We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-14.03%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$1.07B
AUM Growth
-$246M
Cap. Flow
-$27.7M
Cap. Flow %
-2.58%
Top 10 Hldgs %
57.38%
Holding
61
New
4
Increased
17
Reduced
18
Closed
4

Top Buys

Rank Stock Value
1
XNCR icon
Xencor
XNCR
+$56M
2
RVMD icon
Revolution Medicines
RVMD
+$38.7M
3
CTMX icon
CytomX Therapeutics
CTMX
+$22M
4
BDTX icon
Black Diamond Therapeutics
BDTX
+$11.5M
5
ANAB icon
AnaptysBio
ANAB
+$11.4M

Top Sells

Rank Stock Value
1
ARQL
Arqule Inc
ARQL
+$59.5M
2
RCUS icon
Arcus Biosciences
RCUS
+$44M
3
CYTK icon
Cytokinetics
CYTK
+$41.7M
4
BPMC
Blueprint Medicines
BPMC
+$14.7M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$13.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SURF
51
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$1.84M 0.17%
983,051
-103,200
-10% -$272K
LKFT
52
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.8B
$1.5M 0.14%
+7,674
New +$1.65M
FSTX
53
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$885K 0.08%
237,925
– –
RGLS
54
DELISTED
Regulus Therapeutics
RGLS
$734K 0.07%
159,292
-44,278
-22% -$386K
RCUS icon
55
Arcus Biosciences
RCUS
$3.51B
$535K 0.05%
38,574
-3,540,449
-99% -$44M
EIGR
56
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$463K 0.04%
2,268
-2,518
-53% -$803K
ELDN icon
57
Eledon Pharmaceuticals
ELDN
$257M
$267K 0.02%
38,045
-8,004
-17% -$76.5K
BPMC
58
DELISTED
Blueprint Medicines
BPMC
– –
-183,834
Closed -$14.7M
FRTX
59
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
– –
-9,840
Closed -$664K
CFRX
60
DELISTED
ContraFect Corporation
CFRX
– –
-2,374
Closed -$1.18M
ARQL
61
DELISTED
Arqule Inc
ARQL
– –
-2,978,683
Closed -$59.5M
1 2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2020 Portfolio in Review

As of Q1 2020, BVF Inc held 61 positions worth $1.07B, down 19% from $1.32B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

BVF Inc's Q1 2020 filing shows 4 new, 17 increased, 18 reduced and 4 closed positions. Its largest new stake was Xencor: 1,689,300 shares worth $50.5M. The largest sale was Arqule Inc, an estimated $59.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier.

  • BVF Inc's largest Q1 2020 buy was Xencor: 1,689,300 shares worth $50.5M.
  • BVF Inc added most to CytomX Therapeutics in Q1 2020, an estimated $22M increase.
  • BVF Inc's biggest Q1 2020 reduction was Arcus Biosciences, cutting an estimated $44M.
  • BVF Inc fully exited Arqule Inc in Q1 2020, selling an estimated $59.5M.
  • BVF Inc's ten largest holdings make up 57% of its $1.07B portfolio in Q1 2020.
  • BVF Inc opened 4 new positions and closed 4 in Q1 2020.
  • BVF Inc's portfolio value fell 19% quarter-over-quarter to $1.07B.

Based on BVF Inc's 13F filing for Q1 2020, filed 15 May 2020.